GlassScriptPhysician profile
Muhammad Khan
NPI 1477661957
$590.06
in general payments reported to CMS, 2019-2025
10 companies · $18.19 in 2025
The $18.19 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.85 · 2020: $94.35 · 2021: $69.79 · 2022: $188 · 2023: $51.65 · 2024: $119 · 2025: $18.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $188.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $189.49 | 2020-2024 | Haegarda |
| Regeneron Healthcare Solutions, INC. | $97.16 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $89.94 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $65.68 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $59.47 | 2022 | |
| Genentech USA, INC. | $23.93 | 2024 | Xolair |
| Janssen Pharmaceuticals, INC | $19.65 | 2023 | Xarelto |
| Biocryst US Sales Co., LLC | $18.19 | 2025 | Orladeyo |
| Pfizer INC. | $14.67 | 2021 | |
| Vertical Pharmaceuticals, LLC | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.